Corrigendum re 'Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial' [Eur Urol 2019;76:823–30]

Autor:	Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Claes Ginman, Teppo Huttunen, Ann-Fofie Fransson, Lennat Åström, Lars Franzén, Camilla Thellenberg-Karlsson, Markku J Leskinen, Mihalj Zeke
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Urology MEDLINE Radical radiotherapy medicine.disease Prostate cancer Docetaxel Internal medicine medicine Open label business medicine.drug
Zdroj:	European Urology. 78:e241-e242
ISSN:	0302-2838
DOI:	10.1016/j.eururo.2020.08.035
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5e5987904cb6d9c9dab945615af1a739 https://doi.org/10.1016/j.eururo.2020.08.035 Zobrazit plný text záznamu Full Text from ScienceDirect